Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1

Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1

Autor Felicio, Andre C. Autor UNIFESP Google Scholar
Godeiro-Junior, Clecio Autor UNIFESP Google Scholar
Shih, Ming C. Autor UNIFESP Google Scholar
Borges, Vanderci Autor UNIFESP Google Scholar
Silva, Sonia M. A. Autor UNIFESP Google Scholar
Aguiar, Patricia de Carvalho Autor UNIFESP Google Scholar
Hoexter, Marcelo Q. Autor UNIFESP Google Scholar
Barsottini, Orlando G. P. Google Scholar
Andrade, Luiz A. F. Google Scholar
Bressan, Rodrigo A. Autor UNIFESP Google Scholar
Ferraz, Henrique B. Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
Resumo Despite its relatively high prevalence Parkinson's Disease (PD) is still misdiagnosed in approximately 25% of cases. in this study our aim was to evaluate patients with Clinically Unclear Parkinsonian Syndromes (CUPS) submitted to brain SPECT imaging using the technetium-99m labeled Dopamine Transporter (DAT) tracer TRODAT-1. We recruited 15 subjects with CUPS and matched them with 13 patients with probable PD and 13 healthy control subjects (HCS). A SPECT with TRODAT-1 was performed at the baseline evaluation and patients from the CUPS were followed-up for 2-years to ensure or not PD diagnosis (gold-standard). the mean +/- SD results from Right and Left striatum Binding Potential (BP) were, respectively, 1.08 +/- 0.20 and 1.04 +/- 0.16 in the HCS group, 0.47 +/- 0.16 and 0.53 +/- 0.17 in the PD group, and 0.68 +/- 0.11 and 0.84 +/- 0.17 in the CUPS group. the rate of disagreement between baseline SPECT in the CUPS group as compared to the gold standard diagnosis (clinical diagnosis of PD on follow-up) was of 20%. the sensitivity of the SPECT with TRODAT-1 was 100%, while specificity was 70%. in conclusion, our data provided further information about the role of the technetium-99m labeled tracer TRODAT-1 as a biomarker of DAT reduction that can also be used in the diagnosis of patients with CUPS. (C) 2010 Elsevier By. All rights reserved.
Palavra-chave Clinically Unclear Parkinsonian Syndromes
Parkinson's Disease
SPECT
TRODAT-1
Dopamine transporter
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Fondation Philanthropique Edmond J. Safra
Data de publicação 2010-04-15
Publicado em Journal of the Neurological Sciences. Amsterdam: Elsevier B.V., v. 291, n. 1-2, p. 64-68, 2010.
ISSN 0022-510X (Sherpa/Romeo, fator de impacto)
Publicador Elsevier B.V.
Extensão 64-68
Fonte http://dx.doi.org/10.1016/j.jns.2009.12.024
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000276624200011
Endereço permanente http://repositorio.unifesp.br/handle/11600/32474

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta